3 completed, 1 active not recruiting, 1 unknown, 1 withdrawn. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow margetuximab: new trials by email Literature Review of margetuximab trials Research Report on margetuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer Margetuximab, Tucatinib, Capecitabine - Metastatic Breast Cancer, Advanced Breast Cancer | Phase 2 | Withdrawn | MedSIR | 2022-05-15 | 2022-07-11 | |
| MARGetuximab Or Trastuzumab (MARGOT) Paclitaxel, Pertuzumab, Margetuximab - Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 174 | 2020-07-13 | 2025-11-18 |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine) - Breast Cancer Metastatic | Phase 2 | Unknown | Zai Lab (Shanghai) Co., Ltd. | 123 | 2020-01-13 | 2023-08-22 |
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer margetuximab, Retifanlimab, Tebotelimab - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 / Phase 3 | Completed | MacroGenics | 82 | 2019-09-30 | 2025-06-08 |
| Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab - Gastric Cancer, Stomach Cancer | Phase 1 / Phase 2 | Completed | MacroGenics | 95 | 2016-01-01 | 2025-03-17 |
| Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer Margetuximab - Breast Cancer | Phase 2 | Completed | MacroGenics | 25 | 2013-03-01 | 2025-03-13 |
Breast Neoplasms (3) · Stomach Neoplasms (2) · Esophageal Neoplasms (1) · Recurrence (1)
MacroGenics (3) · Dana-Farber Cancer Institute (1) · MedSIR (1) · Zai Lab (Shanghai) Co., Ltd. (1)
United States (4) · Taiwan (3) · Singapore (2) · South Korea (2) · Canada (1) · China (1) · Germany (1) · Italy (1) · Poland (1) · United Kingdom (1)
Adrienne Waks, MD (1) · Stephen L. Eck, MD, PhD (1)
PMID 32653053, PMID 33263418, PMID 37104758, PMID 38751523, PMID 41811823